Human B7-H4 Protein, His Tag (MALS verified)
分子别名(Synonym)
B7-H4,VTCN1,B7S1,B7h.5
表达区间及表达系统(Source)
Human B7-H4, His Tag (B74-H5222) is expressed from human 293 cells (HEK293). It contains AA Phe 29 - Ala 258 (Accession # NP_078902).
Predicted N-terminus: Phe 29
蛋白结构(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.4 kDa. The protein migrates as 39-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
无菌(Sterility)
Negative
纯度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
含V集结构域的T细胞活化抑制剂1(VTCN1)也称为免疫共刺激蛋白B7-H4、蛋白B7S1、T细胞共刺激分子B7x、B7H4,属于免疫球蛋白超家族和BTN/MOG家族。VTCN1包含两个Ig样V型(免疫球蛋白样)结构域。VTCN1的表达被IL6和IL10上调,并被抗原呈递细胞(APC)上的GM-CSF和IL4抑制。VTCN1/B7-H4通过抑制T细胞的活化、增殖、细胞因子的产生和细胞毒性的发展来负调控T细胞介导的免疫反应。VTCN1参与促进上皮细胞转化。
关键字: B7-H4;B7-H4蛋白;B7-H4重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。